Phosphodiesterase (PDE) Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, France, China - Size and Forecast 2024-2028

Published: Dec 2023

Pages: 165

SKU: IRTNTR73613

Snapshot

Phosphodiesterase (PDE) Inhibitors Market 2024-2028

The global phosphodiesterase (PDE) inhibitors market size is estimated to grow by USD 3.78 billion at a CAGR of 6.85% between 2023 and 2028.

The phosphodiesterase (PDE) inhibitors market has witnessed the advent of new-generation PDE inhibitors in the past few years. In addition to PDE4 and PDE5 inhibitor approvals, the global phosphodiesterase (PDE) inhibitors market has also witnessed the approvals of other PDE inhibitors over the past few years, which is fueling the market growth. In January 2021, Merck announced that the VERQUVO had been approved by the Food and Drug Administration (FDA). It is a soluble guanylate cyclase (sGC) stimulator used to lower the risk of cardiovascular death and heart failure hospitalization. Therefore, such efforts by players to launch new PDE inhibitors in the market and expand the therapeutic applications of the existing PDE inhibitors are anticipated to increase the demand and adoption of PDE inhibitors for the treatment of various diseases, thereby driving market growth during the forecast period.

Technavio has segmented the market into Application, Type, and Geography

The application segment includes oral, topical, and other RoA
The type segment includes PDE5 inhibitors, PDE4 inhibitors, and PDE3 and others
The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Besides analyzing the current market scenario, our report examines historical data from 2018 - 2022.

What will be the size of the Phosphodiesterase (PDE) Inhibitors Market During the Forecast Period?

To learn more about this report, Download Report Sample

Phosphodiesterase (PDE) Inhibitors Market Segmentation by Application, Type, and Geography Analysis

Application Analysis

Oral

The market share growth by the oral segment will be significant during the forecast period. Considering the high therapeutic efficacy of PDE5 inhibitors for the treatment of ED in men, these drugs have gained significant importance over the past few years. PDE5 inhibitors are a class of drugs that block the action of phosphodiesterase type 5 (PDE5) enzyme. Some of the major market players are offering oral PDE5 inhibitors, which are being extensively used for the treatment of ED and are among the major revenue contributors to the market.

Get a glance at the market contribution of various segments Download PDF Sample

The oral segment was valued at USD 5.73 billion in 2018. PDE5 inhibitors are also formulated as sublingual dosage forms. In addition to PDE5 inhibitors, other PDE inhibitors are being extensively used in this dosage form. OTEZLA (apremilast) by Celgene Corp. (Celgene) is an orally administered PDE4 inhibitor used for the treatment of psoriatic arthritis. It is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. Moreover, the rising prevalence of various chronic diseases will ensure continuous adoption of oral PDE inhibitors for their treatment, which would drive the growth of the segment and market during the forecast period.

Type Analysis

PDE5 inhibitors

PDE5 inhibitors commonly include sildenafil, tadalafil, vardenafil, and avanafil. PDE5 inhibitors are a group of drugs most generally used to treat erectile dysfunction (ED). ED is the most common disease found in older men. The global prevalence of erectile dysfunction is projected to grow to 322 million men by 2025. The growing prevalence and demand for efficient treatment of ED are encouraging vendors to introduce effective products. For instance, in June 2023, Futura Medical received FDA approval for its Eroxon, an OTC topical gel for ED. Therefore, the growth of PDE5 inhibitors in the global phosphodiesterase inhibitors market is expected to propel during the forecast period.

PDE4 inhibitors

PDE4 inhibitors work by suppressing the immune system, thereby reducing inflammation. Systemically delivered PDE4 inhibitors have been limited by systemic adverse reactions. Inhaled PDE4 inhibitors may be an option to improve tolerability and determine the maximal therapeutic potential of PDE4 inhibition in the respiratory system. Increasing autoimmune diseases is promoting vendors in the field to launch new products in respective segments. Thus, such factors are expected to boost the growth of the segment in the phosphodiesterase inhibitors market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have explained the regional trends and drivers that will shape the market during the forecast period. North America is the largest region due to large pharmaceutical companies offering both branded and generic PDE inhibitors and a proper regulatory framework for the approval of new drugs in the region. Phosphodiesterase (PDE5) inhibitors are most commonly used to treat ED. ED is widely regarded as the most common form of sexual dysfunction in men, and it becomes more prevalent as men age. It is estimated that anywhere between 30 million to 50 million men in the US deal with ED.

Moreover, the increased disposable income of people is leading to a large number of patients opting for the PDE inhibitors treatment, thereby contributing to the market growth in this region. In addition, the increased focus of key market players on investing in R&D activities to maintain their market position is anticipated to have a positive impact on phosphodiesterase inhibitors market growth during the forecast period.

Buy Full Report Now

Key Phosphodiesterase (PDE) Inhibitors Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Amgen Inc.: The company offers phosphodiesterase inhibitor namely OTEZLA.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Phosphodiesterase (PDE) Inhibitors Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.

Key Phosphodiesterase (PDE) Inhibitors Market Drivers

The rising prevalence of ED is the key factor driving market growth. ED is a medical condition characterized by the inability to achieve erection enough for satisfactory sexual intercourse. The etiology of ED can be attributed to multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia. In addition, the consumption of certain medicines and substance abuse can lead to ED. As most of these factors are related to lifestyle changes, the prevalence of ED is increasing globally.

Furthermore, the corpus cavernosum smooth muscle contraction is defined as the inability of muscles to relax, which can subsequently lead to ED. Considering rapid urbanization, lifestyle changes, including increased tobacco use and alcohol consumption, and high employment stress, young men are more susceptible to ED. The increase in the incidence of ED is expected to boost the adoption of PDE5 inhibitors during the forecast period. Thus, it is expected to propel the growth of the market during the forecast period.

Significant Phosphodiesterase (PDE) Inhibitors Market Trends

The application of new technologies for PDE inhibitor development is the primary trend shaping market growth. PDE enzymes are of 11 types; of these, PDE5 has gained significant attention over the years after its recognition as the major target enzyme for treating ED. PDE5 enzymes have an amino acid sequence and molecular structure similar to PDE6 and PDE11, and hence, first-generation PDE5 inhibitors, such as sildenafil and vardenafil, are also competitive inhibitors of PDE6 and PDE11. Thus, the application of novel technologies for the development of PDE5 inhibitors, which can decrease their cross-reactivity with PDE6 and PDE11 enzymes, is required. For this purpose, a similarity-based virtual screening technique, such as the ZINC database, is used.

In addition, ZINC is a free public resource database that contains more than 20 million small molecular compounds. The database enables researchers to access the chemoinformatics and biological activities of small molecules to aid in drug development and strengthen the understanding of minute differences between two compounds sharing similar molecular structures through virtual screening. Thus, such initiatives are likely to propel the growth of the global phosphodiesterase (PDE) inhibitors market during the forecast period.

Major Phosphodiesterase (PDE) Inhibitors Market Challenges

Increasing the launch of generics is a challenge that affects market growth. In September 2018, Teva launched the generic version of CIALIS (tadalafil) in the US, which is used for the treatment of ED. Following the launch of generic sildenafil and tadalafil, the sales of their branded versions, VIAGRA from Pfizer and CIALIS from Eli Lilly, decreased significantly. For example, in September 2020, research was conducted in which patients with pulmonary arterial hypertension at intermediate risk who switched from phosphodiesterase type 5 inhibitors to riociguat experienced clinical improvement at 24 weeks.

Furthermore, following the loss of patent exclusivity, the generic competition for a product increases, leading to a decrease in the product sales of branded drugs as the generic competitor enters the market with the same product at lower prices. This also increases the threat of new entrants in the market, which, in turn, disrupts the market position of the existing players. Thus, such factors are anticipated to the market growth during the forecast period.

Buy Now Full Report

Key Phosphodiesterase (PDE) Inhibitors Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Phosphodiesterase (PDE) Inhibitors Market Customer Landscape

Segment Overview

The phosphodiesterase (PDE) inhibitors market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.

Application Outlook
- Oral
- Topical
- Other RoA

Type Outlook
- PDE5 inhibitors
- PDE4 inhibitors
- PDE3 and others

Region Outlook
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of World (ROW)
  - Argentina
  - Australia
  - Brazil

Phosphodiesterase (PDE) Inhibitors Market Scope
Report Coverage	Details
Page number	165
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 6.85%
Market Growth 2024-2028	USD 3.78 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	6.15
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 41%
Key countries	US, Germany, UK, France, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Deciphera Pharmaceuticals Inc, Dong A Socio Holdings Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., Viatris Inc., VIVUS LLC, and Zydus Lifesciences Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Phosphodiesterase (PDE) Inhibitors Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the phosphodiesterase (PDE) inhibitors market between 2024 and 2028
Precise estimation of the phosphodiesterase (PDE) inhibitors market size and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies' position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of phosphodiesterase (PDE) inhibitors market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global phosphodiesterase (PDE) inhibitors market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global phosphodiesterase (pde) inhibitors market 2018 - 2022 ($ billion)

4.2 Application Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Application Segment 2018 - 2022 ($ billion)

4.3 Type Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Type Segment 2018 - 2022 ($ billion)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Application

6.1 Market segments
- Exhibit 30: Chart on Application - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Application - Market share 2023-2028 (%)

6.2 Comparison by Application
- Exhibit 32: Chart on Comparison by Application
- Exhibit 33: Data Table on Comparison by Application

6.3 Oral - Market size and forecast 2023-2028
- Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)

6.4 Topical - Market size and forecast 2023-2028
- Exhibit 38: Chart on Topical - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on Topical - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on Topical - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Topical - Year-over-year growth 2023-2028 (%)

6.5 Other RoA - Market size and forecast 2023-2028
- Exhibit 42: Chart on Other RoA - Market size and forecast 2023-2028 ($ billion)
- Exhibit 43: Data Table on Other RoA - Market size and forecast 2023-2028 ($ billion)
- Exhibit 44: Chart on Other RoA - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Other RoA - Year-over-year growth 2023-2028 (%)

6.6 Market opportunity by Application
- Exhibit 46: Market opportunity by Application ($ billion)
- Exhibit 47: Data Table on Market opportunity by Application ($ billion)

7 Market Segmentation by Type

7.1 Market segments
- Exhibit 48: Chart on Type - Market share 2023-2028 (%)
- Exhibit 49: Data Table on Type - Market share 2023-2028 (%)

7.2 Comparison by Type
- Exhibit 50: Chart on Comparison by Type
- Exhibit 51: Data Table on Comparison by Type

7.3 PDE5 inhibitors - Market size and forecast 2023-2028
- Exhibit 52: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ billion)
- Exhibit 53: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ billion)
- Exhibit 54: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)

7.4 PDE4 inhibitors - Market size and forecast 2023-2028
- Exhibit 56: Chart on PDE4 inhibitors - Market size and forecast 2023-2028 ($ billion)
- Exhibit 57: Data Table on PDE4 inhibitors - Market size and forecast 2023-2028 ($ billion)
- Exhibit 58: Chart on PDE4 inhibitors - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on PDE4 inhibitors - Year-over-year growth 2023-2028 (%)

7.5 PDE3 and others - Market size and forecast 2023-2028
- Exhibit 60: Chart on PDE3 and others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 61: Data Table on PDE3 and others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 62: Chart on PDE3 and others - Year-over-year growth 2023-2028 (%)
- Exhibit 63: Data Table on PDE3 and others - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by Type
- Exhibit 64: Market opportunity by Type ($ billion)
- Exhibit 65: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2023-2028 (%)
- Exhibit 68: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 Germany - Market size and forecast 2023-2028
- Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.9 UK - Market size and forecast 2023-2028
- Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.10 China - Market size and forecast 2023-2028
- Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)

9.11 France - Market size and forecast 2023-2028
- Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
- Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
- Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
- Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ billion)
- Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption

11.4 Industry risks
- Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 113: Vendors covered

12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification

12.3 Amgen Inc.
- Exhibit 115: Amgen Inc. - Overview
- Exhibit 116: Amgen Inc. - Product / Service
- Exhibit 117: Amgen Inc. - Key offerings

12.4 AstraZeneca Plc
- Exhibit 118: AstraZeneca Plc - Overview
- Exhibit 119: AstraZeneca Plc - Product / Service
- Exhibit 120: AstraZeneca Plc - Key news
- Exhibit 121: AstraZeneca Plc - Key offerings

12.5 Bayer AG
- Exhibit 122: Bayer AG - Overview
- Exhibit 123: Bayer AG - Business segments
- Exhibit 124: Bayer AG - Key news
- Exhibit 125: Bayer AG - Key offerings
- Exhibit 126: Bayer AG - Segment focus

12.6 Boehringer Ingelheim International GmbH
- Exhibit 127: Boehringer Ingelheim International GmbH - Overview
- Exhibit 128: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 129: Boehringer Ingelheim International GmbH - Key news
- Exhibit 130: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 131: Boehringer Ingelheim International GmbH - Segment focus

12.7 Dong A Socio Holdings Co. Ltd.
- Exhibit 132: Dong A Socio Holdings Co. Ltd. - Overview
- Exhibit 133: Dong A Socio Holdings Co. Ltd. - Product / Service
- Exhibit 134: Dong A Socio Holdings Co. Ltd. - Key offerings

12.8 Dr Reddys Laboratories Ltd.
- Exhibit 135: Dr Reddys Laboratories Ltd. - Overview
- Exhibit 136: Dr Reddys Laboratories Ltd. - Business segments
- Exhibit 137: Dr Reddys Laboratories Ltd. - Key offerings
- Exhibit 138: Dr Reddys Laboratories Ltd. - Segment focus

12.9 Eli Lilly and Co.
- Exhibit 139: Eli Lilly and Co. - Overview
- Exhibit 140: Eli Lilly and Co. - Product / Service
- Exhibit 141: Eli Lilly and Co. - Key news
- Exhibit 142: Eli Lilly and Co. - Key offerings

12.10 GlaxoSmithKline Plc
- Exhibit 143: GlaxoSmithKline Plc - Overview
- Exhibit 144: GlaxoSmithKline Plc - Business segments
- Exhibit 145: GlaxoSmithKline Plc - Key news
- Exhibit 146: GlaxoSmithKline Plc - Key offerings
- Exhibit 147: GlaxoSmithKline Plc - Segment focus

12.11 Pfizer Inc.
- Exhibit 148: Pfizer Inc. - Overview
- Exhibit 149: Pfizer Inc. - Product / Service
- Exhibit 150: Pfizer Inc. - Key news
- Exhibit 151: Pfizer Inc. - Key offerings

12.12 Sanofi SA
- Exhibit 152: Sanofi SA - Overview
- Exhibit 153: Sanofi SA - Business segments
- Exhibit 154: Sanofi SA - Key news
- Exhibit 155: Sanofi SA - Key offerings
- Exhibit 156: Sanofi SA - Segment focus

12.13 Sun Pharmaceutical Industries Ltd.
- Exhibit 157: Sun Pharmaceutical Industries Ltd. - Overview
- Exhibit 158: Sun Pharmaceutical Industries Ltd. - Product / Service
- Exhibit 159: Sun Pharmaceutical Industries Ltd. - Key offerings

12.14 Teva Pharmaceutical Industries Ltd.
- Exhibit 160: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 161: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 164: Teva Pharmaceutical Industries Ltd. - Segment focus

12.15 United Therapeutics Corp.
- Exhibit 165: United Therapeutics Corp. - Overview
- Exhibit 166: United Therapeutics Corp. - Product / Service
- Exhibit 167: United Therapeutics Corp. - Key offerings

12.16 Viatris Inc.
- Exhibit 168: Viatris Inc. - Overview
- Exhibit 169: Viatris Inc. - Business segments
- Exhibit 170: Viatris Inc. - Key news
- Exhibit 171: Viatris Inc. - Key offerings
- Exhibit 172: Viatris Inc. - Segment focus

12.17 Zydus Lifesciences Ltd.
- Exhibit 173: Zydus Lifesciences Ltd. - Overview
- Exhibit 174: Zydus Lifesciences Ltd. - Business segments
- Exhibit 175: Zydus Lifesciences Ltd. - Key offerings
- Exhibit 176: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 177: Inclusions checklist
- Exhibit 178: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 179: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 180: Research methodology
- Exhibit 181: Validation techniques employed for market sizing
- Exhibit 182: Information sources

13.5 List of abbreviations
- Exhibit 183: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

phosphodiesterase (pde) inhibitors market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis